OverviewSuggest Edit

Kineta is a biotechnology company that is engaged in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, west nile virus, and common cold. It offers ShK Analogs for treatment of multiple sclerosis and autoimmune diseases; and RIG-I Pathway, a molecular on/off switch that triggers the human body's immune defenses against virus infection.
TypePrivate
Founded2008
Websitekinetabio.com

Latest Updates

Employees (est.) (Nov 2019)29

Key People/Management at Kineta

Shawn Iadonato

Shawn Iadonato

Ph.D Chief Executive Officer
Craig W. Philips

Craig W. Philips

President
Michael O. Banks

Michael O. Banks

CFO
Kristin Bedard

Kristin Bedard

Ph.D. CSO, Immuno-Oncology and SVP Discovery
Pauline Kenny

Pauline Kenny

J.D. General Counsel
Jacques Bouchy

Jacques Bouchy

SVP Business Development and Corporate Communications
Show more

Kineta Financials and Metrics

Summary Metrics

Founding Date

2008

Kineta total Funding

$42.2 m

Kineta latest funding size

$1.80 m

Time since last funding

3 months ago

Kineta investors

Kineta's latest funding round in August 2019 was reported to be $1.8 m. In total, Kineta has raised $42.2 m
Show all financial metrics

Kineta Online and Social Media Presence

Embed Graph

Kineta News and Updates

Kineta Invited to Participate at October 2019 Investor Conferences

SEATTLE, Oct. 7, 2019 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta has been invited to participate at multiple investor conferences in October...

Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment Conference

SEATTLE, Aug. 28, 2019 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta's management team has been invited to participate at H.C. Wainwright 21st...

Kineta Invited to Participate at Solebury Trout's 9th Annual CEO Roundtable Conference

SEATTLE, Aug. 12, 2019 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta's management team has been invited to participate at Solebury Trout's 9th...

Kineta Blogs

After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patients

The post After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patients appeared first on Kineta Inc..

Kineta Acquires Translation Fund Award $1.8 Million from Welcome Trusts

The post Kineta Acquires Translation Fund Award $1.8 Million from Welcome Trusts appeared first on Kineta Inc..

Kineta Frequently Asked Questions

  • When was Kineta founded?

    Kineta was founded in 2008.

  • Who are Kineta key executives?

    Kineta's key executives are Shawn Iadonato, Craig W. Philips and Michael O. Banks.

  • How many employees does Kineta have?

    Kineta has 29 employees.

  • Who are Kineta competitors?

    Competitors of Kineta include Bicycle Therapeutics, Nuvaira and Nuvaira.